Semaglutide (Generic) - Obeda
Type 2 Diabetes
Key Facts
About Dr. Reddy's Laboratories
Founded in 1984, Dr. Reddy's has evolved from an API manufacturer into a fully integrated global pharmaceutical enterprise with a mission to provide affordable and innovative medicines. Its strategy is built on a four-pillar business model—Generics, API & Services, Innovative Medicines, and Consumer Health—leveraging deep scientific capabilities in complex generics, biosimilars, and novel drug discovery. Recent milestones, including the launch of India's first generic semaglutide and key biosimilar approvals in major markets, underscore its growth trajectory and commitment to addressing unmet patient needs globally.
View full company profileTherapeutic Areas
Other Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Diabetes Management Gel | Gelteq Limited | Formulation Development |
| Tolimidone | Biodexa Pharmaceuticals | Phase 2 |
| Generic Semaglutide Injection (Obeda) | Dr. Reddy's Laboratories | Approved |
| BioChaperone® Lispro | Adocia | Phase 3 |
| BioChaperone® Combo (Insulin Glargine / Lixisenatide) | Adocia | Phase 2 |
| AJN003 (LuCI™) | AltrixBio | Pre-clinical |
| Hepatic Denervation for Type 2 Diabetes | Metavention | Feasibility |
| MVD-1 (SANA) | Eolo Pharma | Discovery |
| Type 2 Diabetes Management | iWel | Development |
| Band-assisted Duodenal Mucosal Resurfacing (DMR) | Endolastic | Pre-clinical |
| REMD-477 (Volagidemab) | REMD Biotherapeutics | Phase 2 (completed) |
| Undisclosed (Targeting IAPP) | Pangolin Therapeutics | Pre-clinical |